Roth Keeps Regeneron (REGN) at 'Buy' Following Q2 Report; Says 'Blocking and Tackling' Continues
Tweet Send to a Friend
Roth Capital affirms Regeneron (Nasdaq: REGN) with a Buy rating and $520 price target following Q2 results and updated guidance ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
